| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: claimed is application of inhibitor of hystondeacetylase (HDAL) N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propene amide for production of medication for treating myeloma and corresponding method of treatment. ^ EFFECT: claimed substance demonstrates activity with respect to cell lines of myeloma in very low nanomolecular range, from 50 nM in contrast to earlier known HDAC inhibitors. ^ 7 cl |
